| |
Cases
(n=370) |
Controls
(n=10,357) |
| Mean Age ± SD (y) |
67.6 ± 12.2 |
59.7 ± 13.5 |
| Mean diabetes duration |
10.5 ± 6.7 |
7.2 ± 6.4 |
| Males (n) |
241 (65.1%) |
5,643 (54.5%) |
| Females (n) |
129 (34.9%) |
4714 (45.5%) |
| Nephropathy (n) |
28 (7.6 %) |
541 (5.2%) |
| Neuropathy (n) |
19 (5.1%) |
396 (3.8%) |
| Retinopathy (n) |
11 (3.0%) |
215 (2.1%) |
| Peripheral artery disease |
44 (11.9%) |
501 (4.8%) |
| Alcohol |
14 (3.8%) |
366 (3.5%) |
| Previous AMI (n) |
80 (21.6%) |
77 (0.7%) |
| Atrial fibrillation |
49 (13.2%) |
848 (8.2%) |
| Insulin users(n) |
198 (53.5%) |
4,547 (43.9%) |
| Biguanid users (n) |
195 (52.6%) |
7,646 (73.8%) |
| β-cell stimulating users (n) |
137 (37.0%) |
3,913 (37.8%) |
| Glitazones users (n) |
2 (0.5%) |
142 (1.4%) |
| DPP-4 inhibitors users (n) |
22 (5.9%) |
1,159 (11.2%) |
| GLP-1: Liraglutide users (n) |
14 (3.8%) |
1,586 (15.3%) |
| GLP-1: Exenatide users (n) |
10 (2.7%) |
396 (3.8%) |
| Antiarrhythmic drugs |
44 (11.9%) |
794 (7.7%) |
| Hypertension (n) |
328 (88.6%) |
8,616 (83.2%) |
| Statins users (n) |
279 (75.4%) |
8,096 (78.2%) |
|
